Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 20;27:4. doi: 10.1186/s40824-023-00342-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 8 — Vera@CLCMP patches improve the accumulation of ubiquitinated proteins by inhibiting the activation of CaMKII. A-H C57BL/6 male mice kept on HFD for 9 weeks had Vera@CLCMP or CLCMP patches applied to the dorsal skin. LFD-fed mice of the same age were used as a negative control. A, C Triton X-100-soluble and-insoluble fractions of liver tissue lysates were immunoblotted with anti-ubiquitin and anti-p62 antibodies. α-tubulin served as a loading control. B, D Band intensities were quantified and normalized to control levels. E Immunohistochemical staining for p62 in liver tissues from mice in each group. Boxed areas are magnified in the bottom panels. Scale bars, 50 μm; 10 μm (insets). F Optical density of p62 immunoreactivity. G Liver tissues were collected from mice in each group and analyzed by immunoblotting with anti-phospho-CaMKII antibody. α-tubulin served as a loading control. H Band intensities were quantified and normalized to the CaMKII intensities. Data is shown as mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant (One-way ANOVA, followed by Tukey’s test)